Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies

Muscle-directed gene therapy with adeno-associated viral (AAV) vectors is undergoing clinical development for treating neuromuscular disorders and for systemic delivery of therapeutic proteins. Although these approaches show considerable therapeutic benefits, they are also prone to induce potent immune responses against vector or transgene products owing to the immunogenic nature of the intramuscular delivery route, or the high doses required for systemic delivery to muscle. Major immunological concerns include antibody formation against viral capsid, complement activation, and cytotoxic T cell responses against capsid or transgene products. They can negate therapy and even lead to life-threatening immunotoxicities. Herein we review clinical observations and provide an outlook for how the field addresses these problems through a combination of vector engineering and immune modulation.

Automated summary

Muscle-directed gene therapy using AAV vectors is promising for treating neuromuscular disorders. However, there are concerns about immune responses against the vector or transgene products. This review discusses clinical observations and future prospects for addressing these issues through vector engineering and immune modulation.